Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

Eli Lilly's stock price shot up by 2.89% on a massive trading volume of 21.27 billion, signaling strong investor interest.

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

It’s understandable. When the path ahead is unclear, the instinct is to pause. To wait.

AI is reshaping life sciences. Learn how compliant, explainable, and genuinely useful systems move from pilot to scale and ...

By 2023, the tone had shifted. Venture capital cooled. According to CB Insights, funding for AI drug discovery start-ups ...

Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly ...

The pharmaceutical industry’s move toward increased U.S.-based manufacturing is changing the landscape of career ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

The sale represents Clever Culture’s fifth engagement with a leading pharma manufacturer, including AstraZeneca, Bristol ...